The Foundation for Innovative New Diagnostics (FIND), a non-profit foundation, provides affordable innovative diagnostic products for developing countries.
The AASLD Liver Meeting organized by the American Association for the Study of Liver Diseases (AASLD) annually assembles more than 9 500 health professionals, as well as private and public stakeholders from the US and the world to exchange leading-edge research and discuss treatment outcomes. At the occasion of The Liver Meeting, together with FIND and HIV Forum’s HCV Drug Development Advisory Group, GD helped convene and co-host an industry-focused strategic meeting “Hepatitis C Diagnostics – the Bottleneck to Unlocking a Global Market” enabling innovation and partnerships with the pharmaceutical and diagnostic industries. GD president Barbara Bulc moderated the event, together with the co-hosts, to provide systems perspectives on how to unlock the global market and end Hepatitis C. Optimal strategies were determined for new diagnostic tests to drive access to treatment and care for hepatitis C in limited-resource settings.
Additional Resources: